Recruiting at 85 sites Phase 3 Crohn's Disease

Crohn's Disease study: Guselkumab

Official title A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

ClinicalTrials.gov ID: NCT05923073

What this study is testing

What is Guselkumab?

An investigational once‑injected medicine being studied for Crohn's Disease in children.

Also referred to as CNTO1959, TREMFYA.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This study is testing whether guselkumab works well for children with Crohn's disease after a year of treatment. It looks at how the drug affects symptoms and the inside of the gut.
Who it's for
You may be able to join if you are a child with moderate to severe Crohn's disease and have responded to guselkumab after 12 weeks.
What's involved
You would receive the drug and have regular check‑ups. Doctors will look at your symptoms and do tests to see how your gut looks.
Time commitment
The study lasts about a year, with visits at the start, after 12 weeks, and at 52 weeks to monitor progress.
  • Phase 3: a large, late-stage study

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 2 to 17

You may be able to join if

  • Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in...
  • Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than...
  • Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or...
  • Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV...

You likely can't join if

  • Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be...
  • Participants must not have an abscess
  • Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline

The study team makes the final eligibility decision.

Where it is enrolling

  • Los Angeles, California, United States
  • Hartford, Connecticut, United States
  • Atlanta, Georgia, United States
  • Indianapolis, Indiana, United States
  • Boston, Massachusetts, United States
  • Morristown, New Jersey, United States
  • New York, New York, United States
  • Dayton, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Fort Worth, Texas, United States
  • Colchester, Vermont, United States
  • Nedlands, Australia
  • South Brisbane, Australia
  • Westmead, Australia
  • Vienna, Austria
  • Brussels, Belgium
  • Ghent, Belgium
  • Leuven, Belgium
  • Campinas, Brazil
  • Curitiba, Brazil

+ 53 more site(s).

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 2 years to 17 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Los Angeles, California, United States; Hartford, Connecticut, United States; Atlanta, Georgia, United States; Indianapolis, Indiana, United States; Boston, Massachusetts, United States; Morristown, New Jersey, United States and 67 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.